Abstract 925P
Background
Response to immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) varies among patients and depends on lesion features. This study evaluates the CD8 validated radiomics signature (RS) on the metastasis of RM-HNSCC patients to predict patient outcomes to nivolumab.
Methods
This study involved patients from the multi-institutional TOPNIVO phase II study (NCT03226756). At least 5 lesions per organ from each patient were delineated from baseline contrast enhanced CT scans. Features were extracted with the LIFEX software (IMIV/CEA, Orsay, France) and the RS was applied. Pre-treatment biopsies were used to quantify CD8 T-cells concentration (CD8C). The prognostic value of the CD8C and the minimum RS (mRS) were assessed, with values below the median classified as cold tumors.
Results
From 330 patients, 275 were eligible for the radiomics project, totaling 1371 lesions. CD8C was quantified from 133 patients providing a pre-treatment biopsy. CD8C was associated with PFS (HR=0.69, [0.49-0.69], P-value=0.042) and OS (HR=0.58, [0.40-0.84], P-value=0.004). The mRS was associated with OS (HR=0.70, [0.54-0.90], P-value=0.006). CD8C and mRS were independently associated with OS (HR=0.60, [0.41-0.88], P-value=0.009; HR=0.52, [0.34-0.77], P-value=0.001, multivariate analysis Table). Table: 925P
| Overall survival (HR [95%CI]) | P-value | Progression free survival (HR [95%CI]) | P-value | |
Age: ≥ 60 (vs ConclusionsThe least infiltrated lesion indicated by the mRS from metastatic lesions provide prognostic value in RM-HNSCC patients. This score could offer a valuable tool for clinicians to individualize management of RM-HNSCC under nivolumab. Clinical trial identificationNCT03226756. Editorial acknowledgementLegal entity responsible for the studyInstitut Gustave Roussy. FundingFondation ARC. DisclosureC. Even: Financial Interests, Personal, Advisory Board: BMS, MSD, Innate Pharma, Merck Serono; Financial Interests, Institutional, Advisory Board: F Star Therapeutics, Novartis, Elevar, BICARA, PDS Biotechnology, GSK, Merus; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, ISA pharmaceutics, MSD, Debiopharma, Ayala, Gilead, GSK, Beigene, Takeda, Genmab, Seagen, Nykode; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, sanofi. Y. Tao: Financial Interests, Institutional, Advisory Board: MSD, Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding: Onxeo, Merck; Financial Interests, Personal and Institutional, Advisory Board: Seagen. G. Lefebvre: Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Merck. A. Daste: Financial Interests, Personal and Institutional, Expert Testimony: Merck; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb, Amgen; Financial Interests, Personal and Institutional, Funding: Merck. E.B. Saada: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Serono, MSD; Financial Interests, Coordinating PI: Novartis; Financial Interests, Institutional, Coordinating PI: Roche. J. Fayette: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Innate Pharma, Merck, Serono, Roche, Pfizer, Hookipa; Non-Financial Interests, Principal Investigator: AstraZeneca, MSD, Pfizer, Meru, Calliditas, Isa. P. Blanchard: Financial Interests, Institutional, Invited Speaker: Ipsen, Sanofi Aventis, Janssen, MSD; Financial Interests, Personal, Invited Speaker, advisory board and speaker at conferences: Bayer; Financial Interests, Institutional, Advisory Board: Becton Dickinson; Financial Interests, Institutional, Full or part-time Employment, Editor in Chief - Clinical and Translational Radiation Oncology: ESTRO. M. Classe: Financial Interests, Personal and Institutional, Member: Sanofi. A. Auperin: Financial Interests, Personal, Advisory Board: MSD. E. Deutsch: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb; Financial Interests, Personal, Funding: MSD, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co.KG; Financial Interests, Personal and Institutional, Advisory Board: Merck. All other authors have declared no conflicts of interest. Resources from the same session1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumorsPresenter: Qizhi Ma Session: Poster session 03 1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumoursPresenter: Toshihiko Doi Session: Poster session 03 1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)Presenter: Samuel Klempner Session: Poster session 03 1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancerPresenter: Omar Saavedra Santa Gadea Session: Poster session 03 1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustionPresenter: Bo Cheng Session: Poster session 03 Resources: Abstract 1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01Presenter: Athanasia Dasargyri Session: Poster session 03 1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTACPresenter: Adel Benlahrech Session: Poster session 03 1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Presenter: Jonathan Riess Session: Poster session 03 1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancerPresenter: Douglas McNeel Session: Poster session 03 1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumorsPresenter: Stephane Champiat Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|